Adeno-sh-β-Catenin Abolishes Ischemic Preconditioning–Mediated Cardioprotection by Downregulation of Its Target Genes VEGF,Bcl-2,and Survivin in Ischemic Rat Myocardium
Restricted accessResearch articleFirst published online August, 2008
Adeno-sh-β-Catenin Abolishes Ischemic Preconditioning–Mediated Cardioprotection by Downregulation of Its Target Genes VEGF,Bcl-2,and Survivin in Ischemic Rat Myocardium
β-Catenin, the downstream target of glycogen synthase kinase-3β (GSK-3β), plays a vital role in ischemic preconditioning (IP)-mediated cardioprotection. In the present study, we investigated the mechanism of IP-mediated cardioprotection through suppression of β-catenin expression by intramyocardial injection of adeno-sh-RNA against β-catenin (BCT) (4 × 108 pfu). Adeno-LacZ (LZ) was used as control. The rats were randomized into (a) LZ + ischemia–reperfusion (IR); (b) LZIPIR; (c) BCTIR; and (d) BCTIPIR. Isolated hearts from each group were subjected to 30 min of I followed by 2 h of R. Both IPIR group hearts were subjected to IP (5 min I + 10 min R; four cycles) before IR. Significant reduction in left ventricular functional recovery (78 vs. 88 mm Hg), dp/dtmax (1,802 vs. 2,189 mm Hg/sec), and aortic flow (4 vs. 9 ml/min) was observed in BCTIPIR compared with LZIPIR at 120 min of reperfusion. Increased infarct size (42 vs. 24%) and apoptotic cardiomyocytes (122 vs. 58 counts/60 HPF) were observed in BCTIPIR compared with LZIPIR. Real-time PCR and Western blot analysis showed significant downregulation in mRNA and protein expression of VEGF, Bcl-2, and survivin in BCTIPIR compared with LZIPIR. These findings indicated for the first time that silencing β-catenin abolished IP-mediated cardioprotection, probably through inhibition of VEGF-Bcl-2 and survivin.Antioxid. Redox Signal. 10, 1475–1485.
Get full access to this article
View all access options for this article.
References
1.
AberleH, BauerA, StappertJ, KispertA, KemlerR. beta-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J, 16:3797–3804. 1997.
2.
AlkhulaifiAM. Preconditioning the human heart during aorto-coronary bypass surgery. J Cardiovasc Surg, 8:270–275. 1994.
3.
BehrensJ, von KriesJP, KühlM, BruhnL, WedlichD, GrosschedlR, BirchmeierW. Functional interaction of bold beta-catenin with the transcription factor LEF-1. Nature, 382:638–642. 1996.
FerdinandyP, SchulzR, BaxterGF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev, 59:418–458. 2007.
10.
FrameS, CohenP, BiondiRM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell, 7:1321–1327. 2001.
11.
FukudaS, KagaS, SasakiH, ZhanL, ZhuL, OtaniH, KalfinRK, DasD, MaulikN. Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction. J Mol Cell Cardiol, 36:547–559. 2004.
12.
GaoZH, SeelingJM, HillV, YochumA, VirshupDM. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc Natl Acad Sci U S A, 99:1182–1187. 2002.
HaegelH, LarueL, OhsugiM, FedorovL, HerrenknechtK, KemlerR. Lack of beta-catenin affects mouse development at gastrulation. Development, 121:3529–3537. 1995.
15.
HalestrapAP, ClarkeSJ, KhaliulinI. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta, 1767:1007–1031. 2007.
16.
HallRA, LefkowitzRJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res, 91:672–680. 2002.
17.
HartMJ, de los SantosR, AlbertIN, RubinfeldB, PolakisP. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol, 8:573–581. 1998.
18.
HausenloyDJ, TsangA, YellonDM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med, 15:69–75. 2005.
19.
HuelskenJ, VogelR, BrinkmannV, ErdmannB, BirchmeierC, BirchmeierW. Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol, 148:567–578. 2000.
20.
IshikawaF, MiyazonoK, HellmanU, DrexlerH, WernstedtC, HagiwaraK, UsukiK, TakakuF, RisauW, HeldinCH. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature, 338:557–562. 1989.
21.
KagaS, ZhanL, AltafE, MaulikN. Glycogen synthase kinase-3β/β-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol, 40:138–147. 2006.
22.
KawataH, YoshidaK, KawamotoA, KuriokaH, TakaseE, SasakiY, HatanakaK, KobayashiM, UeyamaT, HashimotoT. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase Ce in the rat ischemic myocardium. Circ Res, 88:696–704. 2001.
KusanoS, Raab-TraubN. I-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol, 22:6393–6405. 2002.
25.
MarettoS, CordenonsiM, DupontS, BraghettaP, BroccoliV, HassanAB, VolpinD, BressanGM, PiccoloS. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A, 100:3299–3304. 2003.
26.
MaulikN, DasDK. Potentiation of angiogenic response by ischemic and hypoxic preconditioning of the heart. J Cell Mol Med, 6:13–24. 2002.
27.
MillerJR, HockingAM, BrownJD, MoonRT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene, 18:7860–7872. 1999.
28.
NawrothR, PoellG, RanftA, KloepS, SamulowitzU, FachingerG, GoldingM, ShimaDT, DeutschU, VestweberD. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J, 21:4885–4895. 2002.
29.
PenumathsaSV, KoneruS, ThirunavukkarasuM, ZhanL, PrasadK, MaulikN. Secoisolariciresinol diglucoside: relevance to angiogenesis and cardioprotection against ischemia-reperfusion injury. J Pharmacol Exp Ther, 320:951–959. 2007.
30.
PenumathsaSV, ThirunavukkarasuM, KoneruS, JuhaszB, ZhanL, PantR, MenonVP, OtaniH, MaulikN. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol, 42:508–516. 2007.
31.
ReyaT, CleversH. Wnt signalling in stem cells and cancer. Nature, 434:843–850. 2005.
32.
RubinfeldB, AlbertI, PorfiriE, FiolC, MunemitsuS, PolakisP. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science, 272:974–975. 1996.
33.
SkurkC, MaatzH, RocnikE, BialikA, ForceT, WalshK. Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res, 96:308–318. 2005.
34.
SuiG, ShiY. Gene silencing by a DNA vector-based RNAi technology. Methods Mol Biol, 309:205–218. 2005.
35.
SuiG, SoohooC, Affar elB, GayF, ShiY, ForresterWC, ShiY. A DNA vector based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A, 99:5515–5520. 2002.
36.
ThirunavukkarasuM, PenumathsaSV, KoneruS, JuhaszB, ZhanL, OtaniH, BagchiD, DasDK, MaulikN. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med, 43:720–729. 2007.
37.
TongH, ChenW, SteenbergenC, MurphyE. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res, 87:309–315. 2000.
38.
TongH, ImahashiK, SteenbergenC, MurphyE. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res, 90:377–379. 2002.
39.
TsaiJN, LeeCH, JengH, ChiWK, ChangWC. Differential expression of glycogen synthase kinase 3 genes during zebrafish embryogenesis. Mech Dev, 91:387–391. 2000.
40.
YellonDM, DanaA. The preconditioning phenomenon: a tool for the scientist or a clinical reality?Circ Res, 87:543–550. 2000.
41.
YuanH, MaoJ, LiL, WuD. Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J Biol Chem, 274:30419–30423. 1999.
